Overview

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib...

Open

$0.00

Prior close

$58.49

Today's high

$0.00

Today's low

$0.00

52 Week high

$59.72

52 Week low

$33.76

News

MarketBeat • 1 day ago • EXEL

Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B

Seeking Alpha • 3 days ago • EXEL

Exelixis, Inc. (EXEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

MarketBeat • 4 days ago • EXEL

Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle

Zacks Investment Research • 4 days ago • EXEL

Here's Why Exelixis (EXEL) is a Strong Growth Stock

MarketBeat • 5 days ago • EXEL

Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises